In this position, Mr Kurland will be responsible for directing Xoma’s financial strategy, accounting, financial planning and investor relations functions.
Prior to joining Xoma, Mr Kurland served as CFO of Bayhill Therapeutics, Corcept Therapeutics and Genitope. Mr Kurland has received his JD and MBA degrees from the University of Chicago and his BS degree from Lehigh University.
Steve Engle, chairman and CEO of Xoma, said: “Fred is a seasoned financial executive with over 30 years of experience in biotechnology and pharmaceutical companies including Aviron/MedImmune, Protein Design Labs and Syntex/Roche. He will be a very valuable addition to Xoma’s executive team, particularly as our anti-IL-1 beta blocker XOMA 052 advances into Phase II trials.”